Cordlife has faced severe regulatory penalties, including strict government-mandated suspensions issued by the Ministry of Health of Singapore. Following major investigative audits that uncovered significant operational lapses, temperature control failures in storage tanks, and governance issues, authorities ordered the company to stop collecting, testing, processing, and storing new cord blood units, penalizing its commercial operations heavily.